| Subscribe To Our Free Newsletter |
Cipla Q2 Preview: Analysts expect lukewarm growth in sales, profit
Analysts expect Cipla to register a low single digit rise in the topline and bottomline, with margins being impacted by modest sales in the US and domestic formulations
